Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia Article Swipe
Related Concepts
Dolutegravir
Integrase inhibitor
Elvitegravir
Medicine
Viral load
Regimen
Raltegravir
Drug resistance
Integrase
Internal medicine
Virology
Tolerability
Genotyping
Resistance mutation
Maraviroc
Gastroenterology
Human immunodeficiency virus (HIV)
Antiretroviral therapy
Adverse effect
Genotype
Biology
Reverse transcriptase
Polymerase chain reaction
Microbiology
Biochemistry
Gene
Christine Katlama
,
Cathia Soulié
,
Fabienne Caby
,
Alexis Denis
,
Catherine Blanc
,
L Schneider
,
M.A. Valantin
,
Roland Tubiana
,
Myriam Kirstetter
,
E. Valdenassi
,
Thuy Nguyen
,
Gilles Peytavin
,
Vincent Cálvez
,
Anne‐Geneviève Marcelin
·
YOU?
·
· 2016
· Open Access
·
· DOI: https://doi.org/10.1093/jac/dkw186
· OA: W2418845662
YOU?
·
· 2016
· Open Access
·
· DOI: https://doi.org/10.1093/jac/dkw186
· OA: W2418845662
Dolutegravir has the potency to be further investigated as a single ART in randomized studies, particularly in patients with no prior exposure to integrase inhibitors.
Related Topics
Finding more related topics…